Zacks Research Expects Stronger Earnings for Veeva Systems

Veeva Systems Inc. (NYSE:VEEV) – Equities research analysts at Zacks Research lifted their Q3 2026 EPS estimates for Veeva Systems in a research report issued to clients and investors on Wednesday, September 17th. Zacks Research analyst Team now expects that the technology company will earn $1.38 per share for the quarter, up from their previous estimate of $1.31. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ Q4 2026 earnings at $1.31 EPS, FY2026 earnings at $5.55 EPS, Q1 2027 earnings at $1.38 EPS, Q2 2027 earnings at $1.43 EPS, FY2027 earnings at $5.71 EPS, Q1 2028 earnings at $1.63 EPS, Q2 2028 earnings at $1.71 EPS and FY2028 earnings at $6.91 EPS.

Other equities research analysts also recently issued research reports about the stock. Raymond James Financial reiterated an “outperform” rating and set a $340.00 target price (up previously from $310.00) on shares of Veeva Systems in a research note on Thursday, August 28th. Morgan Stanley raised their price objective on shares of Veeva Systems from $210.00 to $222.00 and gave the company an “underweight” rating in a research report on Thursday, August 28th. Wells Fargo & Company raised their price objective on shares of Veeva Systems from $300.00 to $326.00 and gave the company an “overweight” rating in a research report on Tuesday, August 26th. UBS Group raised their price objective on shares of Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a research report on Thursday, August 28th. Finally, JPMorgan Chase & Co. upgraded shares of Veeva Systems from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $290.00 to $330.00 in a research report on Monday, September 8th. Seventeen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $301.48.

Veeva Systems Stock Performance

Shares of VEEV opened at $276.98 on Monday. Veeva Systems has a fifty-two week low of $200.30 and a fifty-two week high of $296.72. The company has a market capitalization of $45.40 billion, a price-to-earnings ratio of 56.87, a price-to-earnings-growth ratio of 2.15 and a beta of 0.95. The firm has a 50-day simple moving average of $280.65 and a 200-day simple moving average of $259.41.

Insider Buying and Selling

In other news, SVP Jonathan Faddis sold 720 shares of Veeva Systems stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $285.62, for a total transaction of $205,646.40. Following the completion of the sale, the senior vice president directly owned 7,902 shares in the company, valued at approximately $2,256,969.24. This trade represents a 8.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Priscilla Hung sold 171 shares of Veeva Systems stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $284.40, for a total transaction of $48,632.40. Following the sale, the director owned 3,966 shares of the company’s stock, valued at approximately $1,127,930.40. The trade was a 4.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,063 shares of company stock valued at $302,955. Insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Veeva Systems by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 14,971,425 shares of the technology company’s stock worth $4,311,471,000 after purchasing an additional 210,859 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Veeva Systems by 3.7% during the 2nd quarter. Alliancebernstein L.P. now owns 5,705,648 shares of the technology company’s stock worth $1,643,113,000 after purchasing an additional 205,997 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Veeva Systems by 0.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 5,203,867 shares of the technology company’s stock worth $1,205,372,000 after purchasing an additional 34,169 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Veeva Systems by 20.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock worth $924,754,000 after purchasing an additional 689,700 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Veeva Systems by 2.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,316,274 shares of the technology company’s stock worth $955,030,000 after purchasing an additional 85,516 shares in the last quarter. 88.20% of the stock is owned by hedge funds and other institutional investors.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.